Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Jul 26, 2022; 14(7): 382-391
Published online Jul 26, 2022. doi: 10.4330/wjc.v14.i7.382
COVID-19 vaccine-associated myocarditis
Michael C Morgan, Lavannya Atri, Sean Harrell, Wael Al-Jaroudi, Adam Berman
Michael C Morgan, Lavannya Atri, Sean Harrell, Wael Al-Jaroudi, Division of Cardiology, Medical College of Georgia, Augusta, GA 30912, United States
Adam Berman, Baptist Heart, Baptist Medical Center, Jackson, MS 39202, United States
Adam Berman, Department of Population Health Sciences, Medical College of Georgia, Augusta, GA 30912, United States
Author contributions: Morgan MC and Atri L wrote the paper; Harrell S, Al-Jaroudi W and Berman A made critical revisions and added content to the manuscript; Berman A conceived the topic and provided oversight of the writing, editing and submission process.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Michael C Morgan, BSc, Division of Cardiology, Medical College of Georgia, 1120 15th Street, Augusta, GA 30912, United States. mimorgan@augusta.edu
Received: January 16, 2022
Peer-review started: January 16, 2022
First decision: March 16, 2022
Revised: March 30, 2022
Accepted: June 18, 2022
Article in press: June 18, 2022
Published online: July 26, 2022
Abstract

Myocarditis is now recognized as a rare complication of coronavirus disease 2019 (COVID-19) mRNA vaccination, particularly in adolescent and young adult males. Since the authorization of the Pfizer-BioNTech™ and Moderna™ mRNA vaccines targeting the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein, the Centers for Disease Control and Prevention (CDC) has reported 1175 confirmed cases of myocarditis after COVID-19 vaccination in individuals ages 30 years and younger as of January 2022. According to CDC data in June 2021, the incidence of vaccine-mediated myocarditis in males ages 12-29 years old was estimated to be 40.6 cases per million second doses of COVID-19 mRNA vaccination administered. Individuals with cases of COVID-19 vaccine-mediated myocarditis typically present with acute chest pain and elevated serum troponin levels, often within one week of receiving the second dose of mRNA COVID-19 vaccination. Most cases follow a benign clinical course with prompt resolution of symptoms. Proposed mechanisms of COVID-19 vaccine myocarditis include molecular mimicry between SARS-CoV-2 spike protein and self-antigens and the triggering of preexisting dysregulated immune pathways in predisposed individuals. The higher incidence of COVID-19 vaccine myocarditis in young males may be explained by testosterone and its role in modulating the immune response in myocarditis. There is limited data on long-term outcomes in these cases given the recency of their occurrence. The CDC continues to recommend COVID-19 vaccination for everyone 5 years of age and older given the greater risk of serious complications related to natural COVID-19 infection including hospitalization, multisystem organ dysfunction, and death. Further study is needed to better understand the immunopathology and long-term outcomes behind COVID-19 mRNA vaccine-mediated myocarditis.

Keywords: COVID-19, SARS-CoV-2, mRNA vaccine, Myocarditis, Pericarditis

Core Tip: In this review article, we aim to synthesize the current literature surrounding coronavirus disease 2019 (COVID-19) vaccine-mediated myocarditis. COVID-19 mRNA vaccination has been associated with increased cases of myocarditis, particularly in the adolescent and young adult male population. Presentation typically occurs several days following administration of the second dose of a COVID-19 mRNA vaccination. As the world continues to vaccinate against COVID-19, understanding this vaccine-related adverse event is clinically important. Potential mechanisms are reviewed, and current clinical recommendations are discussed.